A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene

[1]  Robert A. Weinberg,et al.  Ras oncogenes: split personalities , 2008, Nature Reviews Molecular Cell Biology.

[2]  E. Lander,et al.  Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[3]  Ji Luo,et al.  Cancer Proliferation Gene Discovery Through Functional Genomics , 2008, Science.

[4]  S. Haggarty,et al.  Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. , 1999, Science.

[5]  Timothy J Mitchison,et al.  Small molecules, big impact: a history of chemical inhibitors and the cytoskeleton. , 2002, Chemistry & biology.

[6]  David E. Misek,et al.  Gene-expression profiles predict survival of patients with lung adenocarcinoma , 2002, Nature Medicine.

[7]  P. Jackson,et al.  The Evi5 Oncogene Regulates Cyclin Accumulation by Stabilizing the Anaphase-Promoting Complex Inhibitor Emi1 , 2006, Cell.

[8]  M. Kirschner,et al.  Regulation of Cdc25C by ERK-MAP Kinases during the G2/M Transition , 2007, Cell.

[9]  Carlo Rago,et al.  Mutant PIK3CA promotes cell growth and invasion of human cancer cells. , 2005, Cancer cell.

[10]  A. Giaccia,et al.  The human Ha-ras oncogene induces genomic instability in murine fibroblasts within one cell cycle. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Daigo Inoue,et al.  A direct link of the Mos–MAPK pathway to Erp1/Emi2 in meiotic arrest of Xenopus laevis eggs , 2007, Nature.

[12]  Ji Luo,et al.  Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction , 2009, Cell.

[13]  Hongmao Sun,et al.  Selective small-molecule inhibitor reveals critical mitotic functions of human CDK1. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Igor Jurisica,et al.  Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study , 2008, Nature Medicine.

[15]  Stephen S. Taylor,et al.  Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery , 2008, Nature.

[16]  A. Catling,et al.  Active MAP Kinase in Mitosis: Localization at Kinetochores and Association with the Motor Protein CENP-E , 1998, The Journal of cell biology.

[17]  William C Hahn,et al.  Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. , 2003, Cancer cell.

[18]  AC Tose.  Cell , 1993, Cell.

[19]  S. Elledge,et al.  Identification of the FANCI Protein, a Monoubiquitinated FANCD2 Paralog Required for DNA Repair , 2007, Cell.

[20]  J. Ferrell,et al.  Requirement for MAPK activation for normal mitotic progression in Xenopus egg extracts. , 1998, Science.

[21]  J. Peters,et al.  Emi1 Is a Mitotic Regulator that Interacts with Cdc20 and Inhibits the Anaphase Promoting Complex , 2001, Cell.

[22]  R. Rosenfeld.  Nature , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[23]  J. Peters.  The anaphase promoting complex/cyclosome: a machine designed to destroy , 2006, Nature Reviews Molecular Cell Biology.

[24]  Tomoko Nishiyama,et al.  Phosphorylation of Erp1 by p90rsk is required for cytostatic factor arrest in Xenopus laevis eggs , 2007, Nature.

[25]  Liming Yang,et al.  A loss-of-function RNA interference screen for molecular targets in cancer , 2006, Nature.

[26]  K. Kinzler,et al.  Use of isogenic human cancer cells for high-throughput screening and drug discovery , 2001, Nature Biotechnology.

[27]  B. Ness,et al.  Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial. , 1996, Blood.

[28]  Stephen J. Elledge,et al.  Genetic Analysis of the Kinetochore DASH Complex Reveals an Antagonistic Relationship with the Ras/Protein Kinase A Pathway and a Novel Subunit Required for Ask1 Association , 2005, Molecular and Cellular Biology.

[29]  M. Urashima,et al.  IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade. , 1997, Journal of immunology.

[30]  S. Fesik,et al.  Survivin depletion preferentially reduces the survival of activated K-Ras-transformed cells , 2007, Molecular Cancer Therapeutics.

[31]  Patrick J. Paddison,et al.  Second-generation shRNA libraries covering the mouse and human genomes , 2005, Nature Genetics.

[32]  Ralph Weissleder,et al.  Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers , 2008, Nature Medicine.

[33]  U. Klein,et al.  Raf kinase inhibitory protein regulates aurora B kinase and the spindle checkpoint. , 2006, Molecular cell.

[34]  A. Sweet-Cordero,et al.  Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon , 2008, Nature Genetics.

[35]  S. Shirasawa,et al.  Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. , 1993, Science.

[36]  S. Elledge,et al.  Non-Oncogene Addiction and the Stress Phenotype of Cancer Cells , 2007, Cell.

[37]  D Puthier,et al.  High incidence of N and K‐Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis , 2001, Human mutation.

[38]  B. Ness,et al.  Activation of N-ras and K-ras induced by interleukin-6 in a myeloma cell line: implications for disease progression and therapeutic response , 2002, Oncogene.

[39]  R. Kaiser,et al.  Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  Xiaoling Wang,et al.  Cancer cells and normal cells differ in their requirements for Thoc1. , 2007, Cancer research.

[41]  Péter Lénárt,et al.  Polo on the Rise-from Mitotic Entry to Cytokinesis with Plk1. , 2008, Developmental cell.

[42]  P. Jackson,et al.  Plk1 regulates activation of the anaphase promoting complex by phosphorylating and triggering SCFbetaTrCP-dependent destruction of the APC Inhibitor Emi1. , 2004, Molecular biology of the cell.

[43]  A. Ullrich,et al.  Targeting polo-like kinase 1 for cancer therapy , 2006, Nature Reviews Cancer.

[44]  Stephen J. Elledge,et al.  Profiling Essential Genes in Human Mammary Cells by Multiplex RNAi Screening , 2008, Science.

[45]  Péter Lénárt,et al.  BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo , 2007, Current Biology.

[46]  J. Minna,et al.  The RASSF1A Tumor Suppressor Restrains Anaphase-Promoting Complex/Cyclosome Activity during the G1/S Phase Transition To Promote Cell Cycle Progression in Human Epithelial Cells , 2008, Molecular and Cellular Biology.

[47]  Brian H. Dunford-Shore,et al.  Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.

[48]  J. Yates,et al.  Bora and the Kinase Aurora A Cooperatively Activate the Kinase Plk1 and Control Mitotic Entry , 2008, Science.

[49]  M. Campbell,et al.  PANTHER: a library of protein families and subfamilies indexed by function. , 2003, Genome research.

[50]  Erich A. Nigg,et al.  Polo-like kinases and the orchestration of cell division , 2004, Nature Reviews Molecular Cell Biology.

[51]  S. Fesik,et al.  Identification of Ras-related nuclear protein, targeting protein for xenopus kinesin-like protein 2, and stearoyl-CoA desaturase 1 as promising cancer targets from an RNAi-based screen. , 2007, Cancer research.

[52]  R. Deshaies,et al.  COP9 Signalosome A Multifunctional Regulator of SCF and Other Cullin-Based Ubiquitin Ligases , 2003, Cell.